🔎 Trials Near Me

መነሻ › ትሪፕል-ኔጌቲቭ የደረት ካንሰር › ማሳቹሴትስ › Boston

በBoston፣ MA ለትሪፕል-ኔጌቲቭ የደረት ካንሰር የሚደረጉ ክሊኒካዊ ጥናቶች

ለትሪፕል-ኔጌቲቭ የደረት ካንሰር የሚደረጉ 26 ጥናቶች በBoston እና በአካባቢው ባሉ ቦታዎች (በወደ 30 ማይል ውስጥ) ተሳታፊዎችን እየፈለጉ ነው። ማን መሳተፍ እንደሚችል እና የጥናት ቡድኑን እንዴት መገናኘት እንደሚቻል ለማየት ጥናቱን ክፈቱ።

Official study text (English)

ለጥናት ተሳታፊዎችን እየፈለጉ ነው? በዚህ ገጽ ላይ በ$99 ለ30 ቀናት ያስቀምጡት →

A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

ተሳታዮችን በመፈለግ ላይደረጃ 1
  • Massachusetts General Hospital, Boston
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ2 ኦክቶ 2026 · NCT06465069

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

ተሳታዮችን በመፈለግ ላይደረጃ 1/2
  • Massachusetts General Hospital, Boston
  • Dana Farber Cancer Institute, Boston
እድሜ 12 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ2 ኦክቶ 2026 · NCT04585750

A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors

ተሳታዮችን በመፈለግ ላይደረጃ 1
  • Dana Farber Cancer Institute, Boston
እድሜ 19 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ1 ኦክቶ 2026 · NCT06586957

Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer

ተሳታዮችን በመፈለግ ላይደረጃ 1
  • Dana-Farber Cancer Institute, Boston
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ30 ሴፕቴ 2026 · NCT05422794

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

ተሳታዮችን በመፈለግ ላይደረጃ 3
  • Massachusetts General Hospital Cancer Center ( Site 0091), Boston
  • Dana Farber Cancer Institute ( Site 0090), Boston
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ25 ሴፕቴ 2026 · NCT06966700

Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

ተሳታዮችን በመፈለግ ላይደረጃ 1
  • Massachusetts General Hospital, Boston
  • Dana-Farber Cancer Institute, Boston
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ21 ሴፕቴ 2026 · NCT05983432

A Nurse-Led, Coping and Supportive Intervention for Patients With Triple-Negative Breast Cancer

ተሳታዮችን በመፈለግ ላይ
  • Massachusetts General Hospital, Boston
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ15 ሴፕቴ 2026 · NCT07513311

First in Human Study of TUB-030 in Patients With Advanced Solid Tumors

ተሳታዮችን በመፈለግ ላይደረጃ 1/2
  • Massachusetts General Hospital, Boston
  • Dana Farber Cancer Institute, Boston
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ11 ሴፕቴ 2026 · NCT06657222

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

ተሳታዮችን በመፈለግ ላይደረጃ 3
  • Massachusetts General Hospital, Boston
  • Beth Israel Deaconess Medical Center, Boston
  • Dana Farber Cancer Institute, Boston
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ9 ሴፕቴ 2026 · NCT05633654

A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors

ተሳታዮችን በመፈለግ ላይደረጃ 1
  • Dana-Farber Cancer Institute, Boston
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ28 ኦገስ 2026 · NCT07029399

A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors

ተሳታዮችን በመፈለግ ላይደረጃ 1
  • Normunity Investigational Site, Boston
  • Normunity Investigational Site, Boston
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ18 ኦገስ 2026 · NCT07182149

Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype

ተሳታዮችን በመፈለግ ላይደረጃ 1
  • Dana-Farber Cancer Institute, Boston
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ17 ኦገስ 2026 · NCT07341867

A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

ተሳታዮችን በመፈለግ ላይደረጃ 2/3
  • Massachusetts General Hospital, Boston
  • Dana-Farber Cancer Institute, Boston
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ10 ኦገስ 2026 · NCT06926868

DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs

ተሳታዮችን በመፈለግ ላይደረጃ 2
  • Dana-Farber Cancer Institute, Boston
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ6 ኦገስ 2026 · NCT06176261

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

ተሳታዮችን በመፈለግ ላይደረጃ 1/2
  • Massachusetts General Hospital, Boston
  • Dana Farber Cancer Institute, Boston
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ4 ኦገስ 2026 · NCT05579366

Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers

ተሳታዮችን በመፈለግ ላይደረጃ 1
  • Massachusetts General Hospital, Boston
እድሜ ከ18 እስከ 100 · ሁሉም ጾታዎች · የተሻሻለው በ29 ጁላይ 2026 · NCT06562192

A Phase 1 of CTX-8371 in Patients With Advanced Malignancies

ተሳታዮችን በመፈለግ ላይደረጃ 1
  • Beth Israel Deaconess Medical Center, Boston
  • Dana-Farber Cancer Institute, Boston
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ28 ጁላይ 2026 · NCT06150664

Sacituzumab Govitecan In TNBC

ተሳታዮችን በመፈለግ ላይደረጃ 2
  • Dana Farber Cancer Institute, Boston
  • Massachusetts General Hospital, Boston
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ17 ጁላይ 2026 · NCT04230109

Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer

ተሳታዮችን በመፈለግ ላይደረጃ 1
  • Dana-Farber Cancer Institute, Boston
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ13 ጁላይ 2026 · NCT07137416

A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors

ተሳታዮችን በመፈለግ ላይደረጃ 1/2
  • Beth Israel Deaconess Medical Center, Boston
  • Dana-Farber Cancer Institute, Boston
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ29 ጁን 2026 · NCT05377996

A Study of LY4175408 in Participants With Advanced Cancer

ተሳታዮችን በመፈለግ ላይደረጃ 1
  • Massachusetts General Hospital, Boston
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ23 ጁን 2026 · NCT07046923

Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)

ተሳታዮችን በመፈለግ ላይደረጃ 2
  • Dana-Farber Cancer Institute, Boston
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ4 ሜይ 2026 · NCT04434040

Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC

ተሳታዮችን በመፈለግ ላይደረጃ 2
  • Dana Farber Cancer Institute, Boston
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ29 ኤፕሪ 2026 · NCT04468061

This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors

ተሳታዮችን በመፈለግ ላይደረጃ 1
  • Dana Farber Cancer Institute, Boston
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ2 ኤፕሪ 2026 · NCT06451497

A Dose Randomization Study of Bulumtatug Fuvedotin in TNBC Patients Previously Treated With ADCs

ተሳታዮችን በመፈለግ ላይደረጃ 1
  • Massachusetts General Hospital, Boston
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ17 ማርች 2026 · NCT06908928

Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067

ተሳታዮችን በመፈለግ ላይደረጃ 1/2
  • Massachusetts General Hospital, Boston
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ15 ኖቬም 2024 · NCT04787042

በሌሎች ከተሞች ለትሪፕል-ኔጌቲቭ የደረት ካንሰር የሚደረጉ ጥናቶች

በBoston ውስጥ ያሉ ሌሎች ጥናቶች

ከ ClinicalTrials.gov የተገኘ መረጃ፣ በ6 ኦክቶ 2026 የተሰብሰቡ። እያንዳንዱ ጥናት የራሱን ቅድመ ሁኔታ ይወስናል፤ የጥናት ቡድኑ ማን መሳተፍ እንደሚችል ይወስናል።